Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

A new study published in the International Journal of Ophthalmology showed specific optical coherence tomography (OCT) ...

EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient ...

Itepekimab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement and is currently in clinical development programs for chronic rhinosinusitis with nasal polyps ...

Faricimab (Vabysmo) showed greater fluid reduction compared with high-dose aflibercept (Eylea) at 12 weeks in matched ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs; The agreement includes pr ...

The pivotal phase 3 clinical trial is the first of 2 that will evaluate the use of DURAVYU for the treatment of wet age-related macular degeneration.

Bayer announces EMA committee recommends label extension approval for Eylea 8 mg: Berlin Monday, May 26, 2025, 17:00 Hrs [IST] Bayer announced that the Committee for Medicinal Pro ...

This study investigates short-term postinjection IOP changes following aflibercept 8 mg and faricimab, compared with aflibercept 2 mg. Methods This observational, prospective study included 90 ...